Introduction {#S1}
============

Invasive systemic infections caused by fungi have increasingly been recognized and represent relevant cause of mortality and morbidity in growing segment of immunocompromised patients for the last decades ([@B53]; [@B2]). The predisposing conditions are largely associated with changing spectrum of patients (age structure, co-morbidities) who are associated with a more risky therapeutic management such as an extensive surgery or aggressive treatment modalities. The majority of these risk factors are related to impaired immune defense mechanisms (hematological malignancies and transplantations, neutropenia, immunodeficiency, HIV), often as a result of the use of immunosuppressant drugs (e.g., corticosteroids, cyclosporine, biologics), the disruption of skin and mucosa integrity (extensive surgery, catheterization, burns, mucositis), and interference of antibiotics with the indigenous microbiota (dysbiosis) ([@B36]; [@B75]; [@B76]; [@B13]). These conditions make patient population vulnerable to opportunistic pathogens including fungi such as *Aspergillus*, *Candida*, *Cryptococcus* or Mucorales ([@B76], [@B74]; [@B13]). Apart from the main fungal etiology, there is a rare and taxonomically diverse group of opportunistic yeasts belonging to the genera *Galactomyces*, *Trichosporon*, and *Magnusiomyces* (*Saprochaete*), which share morphological characteristics, namely the production of arthroconidia ([@B40]; [@B41]; [@B63]; [@B52]; [@B1]; [@B24]; [@B27]). Most systemic infections caused by those arthroconidial fungi are attributable to two species, *Magnusiomyces capitatus* (synonym *Saprochaete capitata*) and *Trichosporon asahii*. *Saprochaete clavata* has emerged as a new pathogen in hematological patients in French and Italian hospitals ([@B45]; [@B10]; [@B60]; [@B77]; [@B14]; [@B21]; [@B26]; [@B25]; [@B46]). Taxonomy studies showed that *S. clavata* and *M. capitatus* are closely related ([@B19]; [@B34]; [@B69]). Today, three main clades of the arthroconidial genera are discriminated: *Galactomyces* and *Dipodascus* which are associated with the *Geotrichum* anamorphs, while *Magnusiomyces* with the *Saprochaete* species ([@B18]; [@B15]). Recently, owing to the principle the one fungus, one name, dual naming has been replaced and *M. capitatus* (synonym *S. capitata, Dipodascus capitatus*) and *S. clavata* are now accepted ([@B18]; [@B39]). In addition, [@B42] have pointed out that the rules of nomenclature using the oldest valid name and the molecular phylogeny would necessitate renaming *S. clavata* to *Magnusiomyces clavatus*. Majority of characteristics of epidemiology, diagnosis and therapy of *S. clavata* infections are similar to those caused by *M. capitatus* and *T. asahii* ([@B42]). They include frequent recovery from blood, lack of specific diagnostic methods, no specific breakpoints for antifungal susceptibility test results and no optimal therapeutic regimen. Moreover, epidemiological data are scarce; there are only a few details about source and transmission of *S. clavata*, although it has the potential to cause outbreaks ([@B8]).

Here, we present six new cases of severe infection caused by *S. clavata* diagnosed in the hematologic intensive care unit and epidemiological data of hospital recordings of 48 patients colonized with the yeast at the University Hospital, Hradec Králové, Czechia between March 2005 and December 2017, which are discussed in context of other *S. clavata* cases reported in the literature and international registry FungiScope^®^.

Materials and Methods {#S2}
=====================

Patient Information {#S2.SS1}
-------------------

Clinical data of patients with diagnosed *S. clavata* infection were collected including basic demographics, underlying diseases, clinical picture, antifungal therapy, and clinical outcome ([Table 1](#T1){ref-type="table"}). Cases with probable or proven infection classified according to the EORTC/MSG criteria were included ([@B20]). A literature search using PubMed for respective cases was done with the search terms "*Saprochaete*," "*Geotrichum*," "*Dipodascus*," "*Magnusiomyces*," "fungemia," "invasive infection," and "rare mycoses." In addition, cases identified from the FungiScope^®^ registry were selected ([@B67]).

###### 

Baseline characteristics of Czech patients with *Saprochaete clavata* infection.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                          **Patient 1**                                               **Patient 2**                                                      **Patient 3**                                                             **Patient 4**                                                                                            **Patient 5**                          **Patient 6**
  ----------------------------------------------------------------------- ----------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- -------------------------------------- --------------------------------------------------------------------------------------
  Sex                                                                     Male                                                        Female                                                             Female                                                                    Female                                                                                                   Female                                 Female

  Age                                                                     45                                                          61                                                                 63                                                                        58                                                                                                       50                                     66

  Underlying present disease                                              AML -- late relapse                                         AML -- new                                                         AML -- new                                                                AML -- early relapse                                                                                     AML -- late relapse                    DLBCL\
                                                                                                                                                                                                                                                                                                                                                                                                                                   Bile duct obstruction\
                                                                                                                                                                                                                                                                                                                                                                                                                                   Hemorrhagic shock\
                                                                                                                                                                                                                                                                                                                                                                                                                                   *Candida glabrata* septic shock

  Previous diseases/Risk factors                                          AML (alloHSCT)\                                             Cholelithiasis\                                                    Cholelithiasis\                                                           AML (1st alloHSCT)\                                                                                      HSV myocarditis\                       Cholelithiasis\
                                                                          Acute GvHD\                                                 Cholecystectomy\                                                   Cholecystectomy                                                           Acute GvHD\                                                                                              AML (autoHSCT)                         Cholecystectomy
                                                                          Cholelithiasis\                                             Chronic pancreatitis\                                                                                                                        Cervix ca *in situ* (hysterectomy)\                                                                                                             
                                                                          Cholecystectomy\                                            Ovarial cystadenofibroma (adnexectomy)                                                                                                       Renal ca (resection)\                                                                                                                           
                                                                          Common bile duct obstruction (internal biliary drainage)\                                                                                                                                                Colorectal ca (resection, radio)\                                                                                                               
                                                                          HSV infection                                                                                                                                                                                            Chronical anal fissura Recurrent CDI MDS--EB2 (Aza)                                                                                             

  Chemotherapy regimen                                                    Ida-HiDAraC                                                 Chemotherapy 3 + 7 FLAG-Ida                                        1st course Chemotherapy 3 + 7 2nd course of HiDAC                         FLAG-Ida TBI 3Gy + F and 2nd alloHSCT                                                                    Chemotherapy 3 + 7                     SoluMedrol and R-CHOP, intrathecal (hydrocortisone, MTX + AraC)

  **Neutropenia (days)**                                                                                                                                                                                                                                                                                                                                                                                                           

  ANC \< 100/ml                                                           19                                                          45                                                                 5                                                                         20                                                                                                       20                                     8

  ANC 100--500/ml                                                         0                                                           0                                                                  7                                                                         3                                                                                                        0                                      0

  Duration neutropenia (days) ANC \<100/ml at the time positive culture   14                                                          33                                                                 7                                                                         12                                                                                                       8                                      3

  Diabetes mellitus                                                       No                                                          No                                                                 No                                                                        Yes                                                                                                      No                                     No

  Mucositis                                                               Yes, grade III                                              Yes, grade III                                                     Yes, grade II                                                             Yes, grade IV                                                                                            Yes, grade II                          No

  CVC                                                                     Yes                                                         Yes                                                                Yes                                                                       Yes                                                                                                      Yes                                    Yes

  Urinary catheter                                                        Yes                                                         Yes                                                                No                                                                        Yes                                                                                                      Yes                                    Yes

  Nasogastric tube                                                        Yes                                                         Yes                                                                No                                                                        Yes                                                                                                      Yes                                    Yes

  Pulmonary ventilation                                                   Yes                                                         Yes                                                                No                                                                        No                                                                                                       No                                     Yes

  Parenteral nutrition                                                    Yes                                                         Yes                                                                No                                                                        Yes                                                                                                      Yes                                    Yes

  **Prophylaxis**                                                                                                                                                                                                                                                                                                                                                                                                                  

  Antibiotic                                                              Ciprofloxacin                                               Ciprofloxacin                                                      Ciprofloxacin                                                             Ciprofloxacin                                                                                            No                                     Ciprofloxacin

  Antiviral                                                               Acyclovir                                                   Acyclovir                                                          No                                                                        Acyclovir                                                                                                Acyclovir                              No

  Antifungal                                                              Fluconazole                                                 Fluconazole                                                        Fluconazole                                                               Voriconazole                                                                                             Fluconazole                            Fluconazole

  Antibiotic therapy                                                      Meropenem                                                   Teicoplanin                                                        Ciprofloxacin                                                             Linezolid                                                                                                Cephoperazone                          Piperacillin/Taz

                                                                          Vancomycin                                                  Imipenem                                                           Piperacillin/Taz                                                          Meropenem                                                                                                Meropenem                              Meropenem Linezolid

                                                                          Teicoplanin                                                 Cephoperazone                                                      Metronidazole                                                             Levofloxacin                                                                                             Teicoplanin                            Vancomycin

                                                                                                                                      Piperacillin/Taz                                                                                                                                                                                                                                      Cefepime                               Amikacin

                                                                                                                                      Vancomycin                                                                                                                                                                                                                                                                                   

                                                                                                                                      Amikacin                                                                                                                                                                                                                                                                                     

  Antifungal therapy (*S. clavata* infection)                             Amphotericin B (1 mg/kg qD)                                 Amphotericin B (1 mg/kg qD) Lipid-based AMB (Abelcet 5 mg/kg qD)   Lipid-based AMB (Abelcet 5 mg/kg qD) Voriconazole (200 mg i.v. q12 h)     Amphotericin B (0.7--1 mg/kg qD) Lipid-based AMB (Abelcet 5 mg/kg qD) Voriconazole (200 mg p.o. q12 h)   Amphotericin B (0.7--1 mg/kg qD.)      Micafungin (100 mg qD) Voriconazole (200 mg i.v. q12 h)

  Antifungal susceptibility                                               E: AMB 1; FLZ 12; VRZ 3; PSZ 8; CFGN 32                     E: AMB 2; FLZ 128; ITZ 4; VRZ 8; PSZ 32; CFGN 32                   M: AMB 0.5; FLZ 8; ITZ 0.25; VRZ 0.094; PSZ 0.5; AFGN 2; CFGN 8; MFGN 2   M: AMB 0.5; FLZ 48; ITZ 0.25; VRZ 1; PSZ 1; AFGN 16; CFGN 16; MFGN 2; 5FC 0.12                           D: AMB S; FLZ S; ITZ S; KTZ S; 5FC S   M: AMB 1; FLZ 4; ITZ 0.125; VRZ 0.03; PSZ 0.25; AFGN 0.5; CFGN 1; MFGN 0.5; 5FC 0.25

  Outcome Cause of death                                                  Died septic shock, MODS                                     Died progression AML septic shock, MODS brain edema                Survived                                                                  Died septic shock, MODS                                                                                  Died septic shock, MODS                Died septic shock, MODS

  **Culture-positivity for *S. clavata***                                                                                                                                                                                                                                                                                                                                                                                          

  Blood/Other                                                             Yes, 3×/Autopsy (kidney)                                    Yes, 3×/No                                                         Yes, 1×/No                                                                Yes, 3×/Rectum 2×                                                                                        Yes, 2×/Autopsy (lungs) Wound swab     Yes, 2×/Urine Bile
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

5FC -- flucytosine, auto/alloHSCT -- autologous/allogeneic hematopoietic stem cell transplantation, AFGN -- anidulafungin, AMB -- amphotericin B, AML -- acute myeloid leukemia, ANC -- absolute neutrophil count, CDI --

Clostridium difficile

infection, CFGN -- caspofungin, D -- disk test (mm), E -- Etest (MIC, mg/l), FLZ -- fluconazole, GvHD -- graft vs. host disease, HSV -- herpes simplex virus, ITZ -- itraconazole, M -- MIC, mg/l (broth dilution), MFGN -- micafungin, MODS -- multiple organ dysfunction syndrome, PSZ -- posaconazole, S -- susceptible category (disk test), Taz -- tazobactam, VRZ -- voriconazole.

Collection and Identification of Fungal Isolates {#S2.SS2}
------------------------------------------------

All clinical specimens -- cerebrospinal fluid, bronchoalveolar lavage (BAL) fluid, sputum, tracheal aspirate, urine, stool, wound swab, cervicovaginal fluid, punctate, skin adnexa, upper respiratory tract samples -- obtained from patients hospitalized in University Hospital were routinely analyzed in mycological laboratory by inoculating onto mycological agar (SDA) to get individual colonies for further investigation such as biochemical tests (biochemical profile assessment), additional cultivation on Corn-meal agar (description of fungal micromorphology), antifungal susceptibility testing. Most of the conventional diagnostic methods were replaced after availability MALDI TOF mass spectrometry (protein profile assessment). Blood samples were cultivated in the BACTEC system using Mycosis medium or media for aerobic bacteria (Beckton Dickinson Diagnostic Instrument System). In case of BAL fluid, sputum, tracheal aspirate, and urine the samples were quantified after inoculation on SDA by means of calibrating bacteriological loops. Fungal identification including *S. clavata* was based on a combination of microscopic examination of morphological traits on Corn-meal agar, especially arthrospore formation ([Figure 1](#F1){ref-type="fig"}), colony appearance on chromogenic agar (Colorex, Trios, Czechia), and biochemical pattern methods based on the evaluation of urease production, in-house carbon auxanogram assimilation tests (17 carbohydrates and sugar alcohols) (sugar disks provided by ITEST plus, Czechia), and/or using of the API ID32C test (BioMérieux, Czechia). Three blood isolates were additionally identified by MALDI-TOF mass spectrometry (Bruker).

![*Saprochaete clavata* arthroconidia on Corn-Meal agar after 5 days at 35°C (slide culture; magn. ×40).](fmicb-10-02196-g001){#F1}

Criteria for *S. clavata* identification included the formation of arthrospores, the absence of urease production, and assimilation of glucose, cellobiose, variable galactose, and negative xylose. These physiological characteristics seem to be sufficient for routine laboratory discrimination of the main arthroconidial fungi pathogenic for humans, especially between *M. capitatus* and *S. clavata* ([@B69]; [@B42]).

Isolates from Patient 3 and 4 were analyzed by sequencing. DNA was extracted from the strains using a QIAamp^®^ DNA Mini Kit (Qiagen) protocol and the 18S rRNA gene was amplified using PCR ([@B55]). Sequences were analyzed using BLAST at NCBI^[1](#footnote1){ref-type="fn"}^.

Antifungal Susceptibility Testing {#S2.SS3}
---------------------------------

The minimum inhibitory concentration (MIC) was determined using Etest (BioMérieux, Czechia) or Sensititre YeastOne (Trek Diagnostics, BioVendor, Czechia) following the instructions of the manufacturer. Sabouraud dextrose agar (BioMérieux CZ) and Mueller-Hinton agar with 2% glucose (LabMediaServis, Czechia) were culture media for disk test in the period of 1995 to 2005 and 2006 to 2017, respectively ([@B12]). The latter agar was also used in the Etest. Since 2016 the paper disks in agar diffusion method has been replaced with tablets (Neo-Sensitabs, Rosco Diagnostica), but this modification of methodology concerned only two of 55 *S. clavata* isolates tested. All strains were included in the statistical analysis according to the following criteria: one isolate (of the same species) per material and per one patient. Quality control strains of *Candida albicans* ATCC 90028, *Candida krusei* ATCC 6258 and *Candida parapsilosis* ATCC 22019 were included.

Epidemiological Investigation {#S2.SS4}
-----------------------------

The incidence of *S. clavata* strains at the University Hospital Hradec Králové during the period of 1995--2017 was retrospectively evaluated based on the recordings of the laboratory information system and the criteria mentioned above. Blood, cerebrospinal fluid, BAL fluid, sputum, tracheal aspirate, urine, and other clinical specimens were microbiologically investigated.

Cases {#S2.SS5}
-----

Six patients were diagnosed with an infection due to *S. clavata* in the hematologic intensive care unit at our University Hospital between 2005 and 2017 ([Table 1](#T1){ref-type="table"}). The median age was 50.5 years (range 45 to 66 years), five patients (83.3%) were female. Five patients were treated for acute myeloid leukemia (AML) and one for diffuse large B-cell lymphoma (DLBCL). The *S. clavata* infection in all patients was diagnosed based on a positive blood culture ([Figure 2](#F2){ref-type="fig"}). In all patients, their management was complicated by bacterial opportunistic infections and by intensive therapy with broad-spectrum antibiotics and anticancer drugs including cytarabine. Five patients developed septic shock and required the use of artificial ventilation and/or hemodialysis. Histological investigation of necroptic samples demonstrated angioinvasivity of vessels with the tendency to disseminate to various organs, including the peritoneum, liver or spinal cord. Methenamine silver staining showed septate hyphae branching in acute angles unrecognizable from *Aspergillus* mycelium ([Figures 3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). Four patients died of septic complications due to fungal and bacterial infections and concomitant hematologic disease. Two patients survived, but one died from an early relapse of AML later. Only one patient (no. 3) experienced a complete remission of AML. The relevant aspects of the treatment of individual patients are summarized in [Table 1](#T1){ref-type="table"}.

![*Saprochaete clavata* in blood culture. Arthroconidia-like hyphal fragments (Gram staining, magn. ×1000).](fmicb-10-02196-g002){#F2}

![Detail of microcolony of *Saprochaete clavata* invading liver by septated hyphae branching in acute angle (methenamine silver stain, magn. ×400).](fmicb-10-02196-g003){#F3}

![Angioinvasion of spinal cord with hyphae (methenamine silver stain, magn. ×100).](fmicb-10-02196-g004){#F4}

### Patient 1 {#S2.SS5.SSS1}

The male patient was diagnosed with AML 8 years after completing the treatment for Hodgkin lymphoma. The treatment of AML consisted of chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT), which was performed during complete remission. The patient's condition was complicated by a biliary obstruction of unknown etiology and required external biliary drainage. The first relapse of AML occurred after 4 years. The second remission of AML was not achieved after induction chemotherapy. The patient developed fever 20 days after chemotherapy (FLAG-Ida). *S. clavata* was cultured from blood. The patient developed septic shock and died of multiple organ dysfunction syndrome (MODS) 43 days after diagnosing *S. clavata*.

### Patient 2 {#S2.SS5.SSS2}

The female patient previously underwent resection for ovarian cancer. AML was diagnosed 3 years after the completion of the cancer treatment. A complete remission of AML was induced only after a second course of induction chemotherapy. A blood culture was positive for *S. clavata*. During a prolonged pancytopenia (absolute neutrophil count below 100/ml lasted 45 days) septic shock and MODS developed 8 days after diagnosing *S. clavata*. After the completion of treatment irreversible brain damage resulted. Subsequently, the active treatment of AML was terminated and the patient died 3 months after the diagnosis of AML.

### Patient 3 {#S2.SS5.SSS3}

The female patient previously underwent surgical treatment for cholecystitis. Six years later, she was diagnosed with AML. A complete remission was induced with the first course of induction therapy. *S. clavata* infection occurred after a first course of consolidation chemotherapy with high-dose cytarabine. This is the only patient who did not develop a septic shock and recovered hematopoietic function. She is still alive and remains in complete remission 87 months after allogeneic HSCT.

### Patient 4 {#S2.SS5.SSS4}

The female patient previously underwent resection for renal cell carcinoma as well as a resection and radiotherapy for colorectal carcinoma. She continued to suffer from a chronic anal fistula and a recurring *Clostridium* infection. Three years after undergoing radiotherapy patient was diagnosed with myelodysplastic syndrome (MDS) which developed into AML. The leukemia was treated with chemotherapy and allogeneic HSCT (alloHSCT) using a reduced-intensity regimen. Three months after alloHSCT acute graft-versus-host disease (GvHD) affected the skin and later on the intestine as well. The GvHD resolved after adding corticosteroid therapy. At the same time, she presented the first early relapse of AML and a new course of induction therapy (FLAG-Ida) was performed. The patient achieved incomplete remission of AML. The following month she was admitted for gastrointestinal bleeding and paralytic ileus. Due to histological confirmation of acute intestinal GvHD, the patient received corticosteroids in addition to standard supportive therapy. The general condition of the patient was very good and without gastrointestinal GvHD manifestation. Later, after the second alloHSCT, *S. clavata* was isolated from blood and stool. The course of treatment was complicated with septic shock and MODS 7 days after diagnosis *S. clavata*, which ultimately led to death.

### Patient 5 {#S2.SS5.SSS5}

The patient was treated for AML with chemotherapy and autologous peripheral blood stem cell transplantation. Three years later, the patient had a relapse of AML. Group B streptococci and *C. albicans* were cultivated from the nasopharyngeal swab. During a period of deep neutropenia, blood culture was positive for *S. clavata*. Eventually she developed septic shock with MODS and that resulted in death.

### Patient 6 {#S2.SS5.SSS6}

The female patient was treated for DLBCL. Due to infiltration and subsequent external biliary obstruction with a lymphoma, external drainage had to be performed. Following a course of R-CHOP chemotherapy, she developed combined hemorrhagic and septic shock with MODS. After the patient was stabilized, a surgical review identified the origin of the hepatic bleeding and liver packing was provided. Another septic shock occurred 2 weeks after candidemia caused by *C. glabrata*, when blood cultures became positive for *S. clavata*. Afterward, septic shock and MODS developed and the patient died.

Results {#S3}
=======

Overall, 116 strains of *S. clavata* from 54 patients were obtained during the follow-up period. Almost all patients (*n* = 50, 92.6%) were colonized with the species, only six (11.1%) developed an infection with positive blood culture of which four had no other *S. clavata* findings and two were colonized -- one before (biliary drainage fluid) and one after (rectal swab) fungemia. *S. clavata* was first identified in our institution in 2002 and was outnumbered by other arthroconidial species, especially *T. asahii* and *M. capitatus*, every year during the study period; only in 2007 it represented the most numerous species among these fungi ([Figure 5](#F5){ref-type="fig"}). In contrast to other arthroconidial yeasts, female patients were more often colonized with *S. clavata* than males (55.6 vs. 44.4%). The distribution of culture positive findings suggested three main sources of *S. clavata* in the human body: respiratory tract and to a lesser extent, the urogenital tract and the gastrointestinal tract ([Figure 6](#F6){ref-type="fig"}). These sources partially overlapped with colonization potential that can be expressed as repeated isolations from the same material. They are tracheal aspirate, urine samples, and punctate fluid, in which the number of isolates per material was more than doubled compared to other materials with usually one isolate per specimen ([Figure 6](#F6){ref-type="fig"}). The exception was blood where four of six patients had repeated positive blood samples for *S. clavata*. In addition, *S. clavata* was the most common species among the arthroconidial yeasts isolated from the blood (6 × *S. clavata*, 3 × *M. capitatus*, and 2 × *T. asahii*) but there was no previous colonization of any catheter.

![Incidence of *Saprochaete clavata* and arthroconidial fungi at the University Hospital Hradec Kralové. n -- number of isolates (one isolate of a given species per one patient). Other AY -- number of isolates of arthroconidial yeasts (*Galactomyces candidus, Magnusiomyces capitatus, Trichosporon asahii*) without *Saprochaete clavata.*](fmicb-10-02196-g005){#F5}

![Distribution of *Saprochaete clavata* by clinical material at the University Hospital Hradec Kralové in 1995--2017. Isolates -- number of *S. clavata* isolates (including repeated ones per material and per one patient). Patients -- number of *S. clavata* strains per patient without repeated isolates from the same material. BAL -- bronchoalveolar lavage fluid, TAS -- tracheal aspirate.](fmicb-10-02196-g006){#F6}

Prevalence of *S. clavata* in ICU patients was similar to those from standard departments (50.8% in ICU vs. 49.2% in non-ICU), but all fungemic patients were hospitalized at the oncological-hematological department. Most of *S. clavata* isolates came from the patients of this clinic (29.1%), followed by pulmonary (21.8%) and geriatric-metabolic department (14.6%) ([Figure 7](#F7){ref-type="fig"}).

![Distribution of *Saprochaete clavata* isolates by clinic at the University Hospital Hradec Králové in 1995--2017. n -- number of isolates (one isolate of a given species per one patient).](fmicb-10-02196-g007){#F7}

Antifungal susceptibility testing was affected by the method used during study period as the individual methods changed ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). In sum, 13 strains were tested for MICs (Etest, Sensititre YeastOne) and 73 strains for inhibition zones (agar diffusion test). Based on the criteria (see section "Materials and Methods"), 12 and 55 of the strains were included in the analysis, respectively ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). In general, Etest provided higher MICs than broth dilution format (Sensititre YeastOne). Our *S. clavata* strains displayed relatively low MICs against amphotericin B, voriconazole, itraconazole, flucytosine, and partly posaconazole, while the MICs of fluconazole and echinocandins were high ([Table 2](#T2){ref-type="table"}). The results of the disk test varied greatly. For voriconazole, posaconazole, flucytosine and echinocandins MICs corresponded well with the results from the disk test ([Tables 2](#T2){ref-type="table"},[3](#T3){ref-type="table"}).

###### 

Review of *in vitro* susceptibility of *Saprochaete clavata* isolates to antifungal drugs.

  **Specimen (n)**        **Drug**     **AMB**      **AFGN**   **MFGN**   **CFGN**   **PSZ**       **VRZ**        **ITZ**       **FLZ**   **ISZ**       **5FC**      **Source**
  ----------------------- ------------ ------------ ---------- ---------- ---------- ------------- -------------- ------------- --------- ------------- ------------ ------------
  Blood (7)               Etest        0.955        32         3          36.6       9.97          0.676          0.794         18.4                                 This study
  Sputum (2)              n^\#^        0.25--2      32         3          32--48     2--32         0.094--8       0.25--4       4--128                               
  Others^§^ (4)           YeastOne     0.574        1.74       2          8          0.285         0.058          0.092         6.96                    0.091        
                          n = 5        0.5--1       1--2       1--4       2--16      0.12--0.5     0.015--0.5     0.03--0.25    2--32                   0.06--0.12   
  Clinical isolates (4)   CLSI                                 2.25                  4             0.19                                   0.88                       [@B59]
                          M27-A3                               1--4                  4             0.062--0.5                             0.5--2                     
  Human/                  CLSI         0.22         2          6.7                   0.25          0.25           0.27          19        0.54                       [@B42]
  Dishwasher (8)          M27-A3       0.125--0.5   2          2--8                  0.25          0.063--0.5     0.25--0.5     16--32    0.125--1                   
  Blood (3)               Etest        1--1.5       \> 32      \>32       \> 32      0.19--0.5     0.094--0.125                                                      [@B60]
  Blood (3)               YeastOne     0.42         1          0.5        8          0.17          0.05           0.09          2.67                                 [@B21]
                          Sensititre   0.25--0.5    1          0.5        8          0.125--0.25   0.03--0.06     0.03--0.12    2--4                                 
  Blood (45)              EUCAST       0.5                                8          0.5           1                                                    0.25         [@B77]
                          E.Def 7.2    0.125--1                           1--8       0.125--1      0.06--2                                              \<0.125--1   
  Blood (1)               Etest        1                                             0.75          0.064                        12                                   [@B10]
  Blood (1)               EUCAST       0.25                    \>4        \>4        0.5           0.5                          32                      0.25         [@B26]
                          E.Def 9.1                                                                                                                                  
  Clinical isolates (4)   Etest        1.25         3          0.56       \>32       0.16          0.13           0.13          20.3      0.014         16.1         [@B24]
                                       1--2         2--4       0.25--1    \>32       0.032--0.25   0.016--0.25    0.002--0.25   1--32     0.004--0.25   0.06--\>32   
  Blood (1)               MIC test     ≤0.5                                                        0.125          ≤0.125        2                       ≤4           [@B50]
  Blood (18)              YeastOne     0.96                                          0.56          0.34           0.31          17.96     0.71          0.18         [@B25]
                          Sensititre   0.5--1                                        0.25--1       0.03--1        0.12--0.5     8--64     0.12--4       0.06--0.5    
  Blood (1)               YeastOne     0.25         R          R          R          0.25          0.5                          32                      0.12         [@B64]
                          Sensititre                                                                                                                                 

∗

Quantitative test (MIC, mg/ml); GM -- geometric mean; n -- number of isolates.

\#

The number of strains tested with Etest in brackets, AMB (7), VRZ (6), FLZ (5), PSZ (5), ITZ (3), CFGN (3), AFGN (1), MFGN (1). §Laryngeal swab, punctate, urine, drainage fluid. R -- interpreted as resistant according to EUCAST standard (document not specified), AMB -- amphotericin B, 5FC -- flucytosine, AFGN -- anidulafungin, MFGN -- micafungin, CFGN -- caspofungin, PSZ -- posaconazole, VRZ -- voriconazole, ITZ -- itraconazole, FLZ -- fluconazole, ISZ -- isavuconazole.

###### 

Antifungal susceptibility of *Saprochaete clavata* isolates^∗^ by disk diffusion method at the University Hospital, Hradec Králové in the period of 1995--2017.

          **AMB**   **FLZ**   **ITZ**   **VRZ**   **PSZ**   **KTZ**   **CFGN**   **5FC**
  ------- --------- --------- --------- --------- --------- --------- ---------- ---------
  n       60        69        68        53        5         16        5          7
  GM      12.6      15.9      14.8      20.2      18.4      23.6      8.8        35.0
  range   8--25     6--32     9--29     6--33     14--22    18--28    6--12      22--51
  IZ50    13        18        14        20        19        25        9          35
  IZ90    9.5       6         11        15                  19                   

∗

Only isolates that met the following criteria were included in the statistical analysis: one isolate/species per one material and per one patient. GM -- geometric mean (inhibition zone in mm), n -- number of strains, IZ50/IZ90 -- lower limit of inhibition zone (mm) encompassing 50%/90% of isolates tested. AMB -- amphotericin B, FLZ -- fluconazole, ITZ -- itraconazole, VRZ -- voriconazole, PSZ -- posaconazole, CFGN -- caspofungin, 5FC -- flucytosine, KTZ -- ketoconazole.

Review of the literature and FungiScope^®^ register revealed 73 cases of *S. clavata* infections in 10 countries most of which located in the Mediterranean (for details see [Table 4](#T4){ref-type="table"}). Only ten patients were from other regions -- Germany, Serbia, China, and Czechia. The vast majority of patients manifested similar clinical signs and symptoms (neutropenia, fever, positivity of blood culture, dissemination and sepsis or septic shock, diarrhea) at time of diagnosis of *S. clavata* infection. The same was true for underlying conditions, including central venous catheter (CVC), broad-spectrum antibiotic therapy, aggressive chemotherapeutic regimens with cytarabine, and, in case of the French cohort, bacterial digestive decontamination ([@B77]). Most patients were treated with voriconazole and/or lipid-based amphotericin B, but mortality rate was extremely high (\>65%) ([Table 4](#T4){ref-type="table"}). *In vitro* and *in vivo* results confirmed that *S. clavata* is intrinsically resistant to echinocandins ([Table 2](#T2){ref-type="table"}).

###### 

Summary of case characteristics of *Saprochaete clavata* infections from literature and FungiScope^®^.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**           **Country**   **Sex**     **Age**   **Underlying disease**                 **Risk factor^\#^**                                                                                     **Clinical form**                                   **Positive specimen**              **Lab diagnosis**                                                          **Drug**                            **Dosage**                       **Duration**                                    **Outcome**
  ------------------- ------------- ----------- --------- -------------------------------------- ------------------------------------------------------------------------------------------------------- --------------------------------------------------- ---------------------------------- -------------------------------------------------------------------------- ----------------------------------- -------------------------------- ----------------------------------------------- ------------------------
  [@B45]              France        M           14        AML                                    CVC, cytarabine                                                                                         Sepsis                                              Blood                              Blood culture                                                              E: AMB                              ns                               1 day                                           Survived

                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB + VRZ                                                       5 days                                          

                                                                                                                                                                                                                                                                                                                                                                           T: VRZ + 5FC                                                         ns                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    M           59        AML                                    CVC, cytarabine                                                                                         BSI                                                 Blood, urine,                      Blood culture,                                                             P: CFGN                             ns                               7 days                                          Survived

                                                                                                                                                                                                                                                             biopsy (skin)                      GM negative                                                                E: CFGN + L-AMB                     3 mg/kg/d (L-AMB)                7 days                                          

                                                                                                                                                                                                                                                                                                                                                                           E: L-AMB + PSZ                                                       4 days                                          

                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB + 5FC + PSZ                5 mg/kg/d (L-AMB)                7 days                                          

                                                                                                                                                                                                                                                             urine                                                                                                         T: L-AMB + 5FC + VRZ                                                 21 days                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B60]              France        F           46        AML                                    CVC, cytarabine, digestive decontamination (GEN, COL), PIP,AMI,VAN,CIP                                  BSI, disseminated                                   Blood, stool, TAS                  Blood culture, GM positive                                                 P: PSZ\                             ns                               24 days                                         Died
                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB + VRZ\                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                           E: CFGN                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    M           70        AML                                    CVC, digestive decontamination (GEN, COL), PIP,AMI,VAN,CIP                                              BSI, pulmonary                                      Blood                              Blood culture,                                                             E: CFGN                             ns                               4 days                                          Died

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    F           63        AML                                    CVC, digestive decontamination (GEN, COL), PIP,AMI,VAN,CIP                                              BSI, disseminated                                   Blood, stool, TAS                  Blood culture                                                              E: CFGN\                            ns                               6 days (CFGN)\                                  Died
                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB + VORI                                                      10 days (L-AMB + VRZ)                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B21]              Italy         F           36        AML                                    CVC, cytarabine, neutropenia, PIP-Taz, MER                                                              Pulmonary, cholecystitis, hepatosplenic abscesses   Blood, CVC                         Blood culture, betaG \>500 pg/ml, GM negative                              T: L-AMB\                           350 mg qd iv\                    100 days (L-AMB)\                               Survived
                                                                                                                                                                                                                                                                                                                                                                           VRZ (after discharge)               200 mg bid oral                  15 days (FungiScope)                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    F           50        MC lymphoma                            CVC, cytarabine, steroids, neutropenia (\<500 mm^3^)                                                    Pneumonia, splenic infiltrates, sepsis              Blood                              Blood culture, betaG \>500 pg/ml, GM negative                              T: L-AMB\                           200 mg qd iv\                    10 days (L-AMB)\                                Died
                                                                                                                                                                                                                                                                                                                                                                           VRZ (after discharge)               350 mg qd iv                     47 days (L-AMB)                                 

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    M           21        AML                                    Methyl- prednisolone, neutropenia (\<500 mm^3^), PIP-Taz, MER, cytarabine                               Splenic abscesses                                   Blood, CVC                         Blood culture, betaG negative, GM negative                                 T: L-AMB\                           200 mg qd iv\                    12 days (L-AMB)\                                Survived
                                                                                                                                                                                                                                                                                                                                                                           VRZ (after discharge)               600 mg bid oral                  1 day (VRZ)                                     

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B77]              France        F (15)^®^   63        AML (70%)                              Neutropenia (\<500 mm^3^; 90%), cytarabine (78.3%)                                                      BSI (87%),                                          Blood, stool, BAL,                 Blood culture                                                              ns                                  ns                               ns                                              24 (80%) died

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    M (15)^®^   (mean)    ALL (20%)                                                                                                                                      pulmonary (40%),                                    TAS                                (86.7%)                                                                                                                                                                                         6 (20%) survived

                                                          CLM (3.3%)                                                                                                                                     diarrhea (61.5%)                                                                                                                                                                                                                                                                       

                                                          other (6.7%)                                                                                                                                                                                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B10]              France        M           32        AML                                    Cytarabine, IMI, VAN, MET IMI, VAN, MET                                                                 Sepsis, peritonitis, Hepatic lesions                Blood, stool, ascites              Blood culture, GM negative                                                 E: CFGN\                            50 mg qd iv\                     8 days (CFGN)\                                  Survived
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ                              300 mg qd iv\                    35 days (VRZ iv)\                               
                                                                                                                                                                                                                                                                                                                                                                                                               100 mg qd iv                     \>270 days (VRZ po)                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B26]              France        M           27        Aplastic anemia                        CVC, neutropenia, prednisone, PIP-Taz, AMI, MER, LVX                                                    BSI, disseminated                                   Blood, CVC                         Blood culture                                                              E: CFGN\                            50 mg qd iv\                     2 days (CFGN)\                                  Survived
                                                                                                                                                                                                                                                                                                                                                                           \                                   \                                \                                               
                                                                                                                                                                                                                                                                                                                                                                           \                                   \                                \                                               
                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB + VRZ                      200 mg bid iv (L-AMB)\           55 days (L-AMB + VRZ)                           
                                                                                                                                                                                                                                                                                                                                                                                                               400 mg bid iv (VRZ)                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B17]              Brazil        F           6         Hemophagocytic lymphohis- tiocytosis   Auto BMT, CVC, neutropenia                                                                                                                                                                                                                                                T: AMB-D\                           ns                               18 days                                         Died
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ                                                                                                               

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Fungiscope - 831    Turkey        F           37        AML (relapse)                          Neutropenia (\<500 mm^3^)                                                                               BSI                                                 Blood                              Blood culture                                                              T: VRZ                              240 mg bid iv\                   8 days\                                         Survived
                                                                                                                                                                                                                                                                                                                                                                                                               200 mg bid oral                  6 days                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Fungiscope - 1211   Israel        F           17        AML                                    Neutropenia (\<500 mm^3^)                                                                               Disseminated (CNS, liver, spleen)                                                      PCR (CSF)                                                                  E: L-AMB\                           250 mg qd iv\                    12 days\                                        Alive, ongoing therapy
                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB\                           250 mg qd iv\                    27 days L-AMB then 5 days\                      
                                                                                                                                                                                                                                                                                                                                                                           T: 5FC\                             1000 mg 4x oral\                 L-AMB + 5FC\                                    
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ                              200 mg bid iv                    5 days L-AMB + 5FC\                             
                                                                                                                                                                                                                                                                                                                                                                                                                                                208 days L-AMB + 5FC + VRZ                      

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Fungiscope - 1216   Spain         M           48        Lymphoma                               alloHSCT, neutropenia (\<500 mm^3^)                                                                     BSI, disseminated (CNS, liver, lung, spleen)        Blood                              Blood culture, PCR (pleural fluid)                                         E: L-AMB\                           400 mg qd iv\                    3 days (2 days with VRZ)\                       Died
                                                                                                                                                                                                                                                                                                                                                                           E: VRZ\                             200 mg bid iv\                   2 days (with L-AMB)\                            
                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB\                           400 mg qd iv\                    99 (11 days with VRZ, then 31 days with 5FC)\   
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ\                             200 mg bid iv\                   11 days (with L-AMB)\                           
                                                                                                                                                                                                                                                                                                                                                                           T: 5FC\                             37.5 mg 4x iv\                   31 days (with L-AMB)\                           
                                                                                                                                                                                                                                                                                                                                                                           2^nd^ P: PSZ\                       300 mg qd tab\                   92 days (mono)\                                 
                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB\                           400 mg qd iv\                    9 days (with 5FC)\                              
                                                                                                                                                                                                                                                                                                                                                                           T: 5FC                              37.5 mg 4x iv                    9 days (with L-AMB)                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Fungiscope - 604    Germany       M           55        AML (relapse)                          alloHSCT (PBSC), neutropenia (\<500 mm^3^), ICU                                                         BSI                                                 Blood                              Blood culture                                                              E: L-AMB\                           290 mg qd iv\                    5 days\                                         Survived
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ                              200 mg bid po                    30 days                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Fungiscope - 616    Serbia        M           19        ALL (relapse)                          Not neutropenic                                                                                         BSI, pulmonary                                      Blood                              Blood culture                                                              E: CFGN\                            50 mg qd iv 50 mg qd iv          4 days\                                         Died
                                                                                                                                                                                                                                                                                                                                                                           T: CFGN                                                              34 days                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B25]              Italy         M (11)      ns        AML (8),                               ns                                                                                                      BSI                                                 Blood                              Blood culture                                                              ns                                  ns                               ns                                              Ns

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    F (6)                 Hodgkin lymphoma (3)                                                                                                                                                                                                                                                                                                                                                                                                                  

                                                          aplastic anemia (2)                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    ns (1)                surgery (3), ns (2)                                                                                                                                                                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B50]              China         M           10        Acute lymphocytic leukemia             Neutropenia, pancreatitis                                                                               BSI, pulmonary                                      Blood                              Blood culture, GM 1.33, 6.03, beta-G 746 pg/ml                             E: MFGN\                            50 mg qd iv\                     8 days (mono)\                                  Survived
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ\                             150 mg iv q12h\                  15 days (mono)\                                 
                                                                                                                                                                                                                                                                                                                                                                           T: MFGN + VRZ\                      100 mg qd iv + 100 mg iv q12h\   40 days (MFGN + VRZ)\                           
                                                                                                                                                                                                                                                                                                                                                                           \                                   27 mg iv qd                      \                                               
                                                                                                                                                                                                                                                                                                                                                                           T: MFGN + L-AMB                                                      43 days (MFGN + L-AMB)                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B64]              Spain         M           47        Lymphoma                               Neutropenia, prednisone, alloHSCT                                                                       BSI, skin                                           Blood, skin biopsy Brain abscess   Blood culture                                                              T: L-AMB\                           5 mg/kg/d\                       60 days\                                        Died
                                                                                                                                                                                                                                                                                                                                                                           T: 5FC                              37.5 mg 4x iv                    60 days                                         

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  This study          Czechia       M           45        AML                                    CVC, cytarabine, neutropenia, alloHSCT, acute GvHD, cholelithiasis, cholecystectomy, biliary drainage   BSI, disseminated                                   Blood                              Blood culture, GM 0.70\                                                    T: AMB-D\                           75 mg qd iv\                     27 days\                                        Died
                                                                                                                                                                                                                                                                                                (-2 days)^∗^                                                               T: VRZ                              200 mg bid po                    7 days                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    F           61        AML                                    CVC, cytarabine, neutropenia, chronic pancreatitis, cholelithiasis, cholecystectomy                     BSI                                                 Blood                              Blood culture, GM 0.55\                                                    T: AMB-D\                           75 mg qd iv\                     15 days\                                        Died
                                                                                                                                                                                                                                                                                                (+3 days)^∗^                                                               T: AMB-LC                           400 mg qd iv                     6 days                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    F           63        AML                                    CVC, neutropenia (\<500 mm^3^), cholelithiasis, cholecystectomy, cytarabine                             BSI                                                 Blood                              Blood culture, GM 0.18, PCR (sequencing)                                   T: AMB-LC\                          400 mg qd iv\                    4 days\                                         Survived
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ                              200 mg bid po                    9 days                                          

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    F           58        AML                                    CVC, neutropenia (\<500 mm^3^), cytarabine, alloHSCT, acute GvHD                                        BSI, pneumonia                                      Blood, rectum                      Blood culture, GM 0.50 (only with 3^rd^ blood culture), PCR (sequencing)   T: AMB-D\                           50 mg qd iv\                     2 days\                                         Died
                                                                                                                                                                                                                                                                                                                                                                           T: AMB-LC\                          400 mg qd iv\                    7 days\                                         
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ                              200 mg bid po                    4 days (AMB-LC + VRZ)                           

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    F           50        AML                                    CVC, cytarabine, neutropenia, autoHSCT                                                                  BSI, pneumonia                                      Blood, wound swab                  Blood culture                                                              T: AMB-D                            50 mg qd iv                      4 days                                          Died

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

                                    F           66        Lymphoma                               CVC, cytarabine, neutropenia, cholelithiasis, cholecystectomy, *Candida glabrata* fungemia              BSI                                                 Blood, bile, urine                 Blood culture, GM 0.31                                                     T: MFGN (*C. glabrata* fungemia)\   100 mf qd iv\                    12 days (*C. glabrata* fungemia)\               Died
                                                                                                                                                                                                                                                                                                                                                                           T: VRZ                              \                                3 days (*S. clavata*)                           
                                                                                                                                                                                                                                                                                                                                                                                                               200 mg bid po                                                                    

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  [@B46]              Italy         M           6         Bone marrow failure                    Three allo-HSCT neutropenia                                                                             BSI, renal, pulmonary/skin involvement              Blood                              Blood culture                                                              P: L-AMB\                           2.5 mg/kg 2× a week\             16\                                             Survived
                                                                                                                                                                                                                                                                                                                                                                           \                                   3.0 mg/kg/d iv\                  \                                               
                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB\                           10 mg/kg/d iv + 8 mg/kg bid iv   9 days mono\                                    
                                                                                                                                                                                                                                                                                                                                                                           T: L-AMB + VRZ                                                       30 days combo                                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\#

in general, all patients had hematological malignancy with anticancer and antibiotic therapy as predisposing conditions. §-- number of all females/males in the study. ns -- not specified.

∗

--/+ days before/after positive blood culture. 5FC -- flucytosine, ALL -- acute lymphoid leukemia, AMB-D/LC -- amphotericin B deoxycholate/lipid complex, AMI -- amikacin, AML -- acute myeloid leukemia, ANC -- absolute neutrophil count, BAL -- bronchoalveolar lavage fluid, beta-G -- beta-

D

-glucan, BSI -- blood-stream infection, CFGN -- caspofungin, CML -- chronic myeloid leukemia, CIP -- ciprofloxacin, CNS -- central nervous system, COL -- colistin, CVC -- central venous catheter, FLZ -- fluconazole, F/M -- female/male, GEN -- gentamicin, GM -- galactomannan, GvHD -- graft vs. host disease, HSCT -- hematopoietic stem cell transplantation, ICU -- intensive care unit, IMI -- imipenem, L-AMB -- liposomal amphotericin B, LVX -- levofloxacin, MC -- mantle cell, MER -- meropenem, MET -- metronidazole, MFGN -- micafungin, P/E/T -- prophylactic/empirical/targeted therapy, PIP + TAZ (piperacillin + tazobactam), PSZ -- posaconazole, TAS -- tracheal aspirate, VAN -- vancomycin, VRZ -- voriconazole.

Discussion {#S4}
==========

*Saprochaete clavata* together with the *Galactomyces*, *Magnusiomyces*, and *Trichosporon* species represent rare human pathogenic fungi of heterogeneous origin, which share production of arthroconidia. *S. clavata* is almost exclusively confined to systemic, life-threatening infections while the clinical presentation of infections caused by other arthroconidial fungi range from superficial (*Trichosporon* spp.), mucosal (*Galactomyces candidus*), allergic (*Trichosporon* pneumonitis) to systemic forms (*T. asahii, M. capitatus*, and *G. candidus*) ([@B31]; [@B41]; [@B5]; [@B77]; [@B16]; [@B24]; [@B25]; [@B46]; [@B64]). AML is the leading underlying condition for systemic infections caused by *S. clavata* such as for other arthroconidial yeasts ([@B31]; [@B41]; [@B10]; [@B16]).

All epidemiological aspects associated with *S. clavata* are not fully understood. Numbers of isolates of arthroconidial fungi obtained in our hospital during the period of 1995 to 2017 showed a noticeable fluctuation, which corresponded with similar course of fungemia outbreak in the French hospitals (Figure 3 in [@B77]). That can suggest influence of some unknown epidemiological factor(s). All arthroconidial fungi are ubiquitous in nature but *Trichosporon* infections are more frequently described in the United States, while *M. capitatus* prevails in the Mediterranean area (Italy, France, Spain, Turkey, Greece, Tunisia, Israel, Libya, FungiScope^®^) ([@B65]; [@B28]; [@B11]; [@B31]; [@B29]; [@B77]; [@B73]; [@B21]; [@B24]; [@B25]; [@B46]; [@B64]). We found no correlation between temperature in the Czechia and in Eastern Bohemia and the number of isolated *S. clavata* strains during the follow-up period (data not shown).

As regards potential sources of these fungi, main suspicion falls on in-house environment (dishwasher) and food, especially milk and dairy products ([@B7]; [@B37]; [@B82]; [@B77]; [@B4]; [@B32]). It is worth mentioning interpersonal transmission among hospitalized patients as reported during the French outbreak and the potential of fly-to-human transmission as suggested by the positive *S. clavata* isolates from *Drosophila* flies ([@B61]; [@B77]). In line with the reports on other arthroconidial fungi, the respiratory tract seems to be the main ecological niche colonized by *S. clavata* in debilitated patients, whereas the intestine and/or urogenital tract may be less relevant ([Figure 6](#F6){ref-type="fig"}). Metagenomic studies have not revealed *S. clavata* in human microbiota in contrast to the species of *Galactomyces* and *Trichosporon*, which are part of the gut microbiome and together with *Candida, Malassezia*, and sporulating molds constitute core gut mycobiota ([@B33]; [@B38]; [@B3]; [@B47]).

To date, little is known about the virulence mechanisms of *S. clavata*. There is no data about biofilm production of *S. clavata*, only indirect suggestions based on a close relation between the presence of CVC and a positive blood culture (this study, [@B31]; [@B10]; [@B60]; [@B77]; [@B21]). Compared to *T. asahii*, *S. clavata* is more genetically monomorphic ([@B71]; [@B77]). Two main clades (A and B) of *S. clavata* were identified during the French outbreak ([@B77]). The clinical significance of both clades was similar in most characteristics, including their susceptibility to antifungal drugs. Although clade A exhibited lower virulence expressed by longer survival of experimentally infected mice, it was responsible for most cases of the French outbreak ([@B77]). That indicates higher human-to-human transmissibility of the clade A or its better adaptability to unknown environment (source), which can be responsible for an increased exposure of vulnerable patients to this clade ([@B77]).

Clinically, *S. clavata* infections are difficult to distinguish from *M. capitatus* infections and the majority of other invasive mycoses. No reliable diagnostic tests are available and thus, in the absence of any specific signs and symptoms, positive blood cultivation remains indicative for this mycosis. It is difficult to establish an early diagnosis, which increases the likelihood for the optimal timing of antifungal treatment before the development of advanced and more difficult-to-control stage of the infection. There is no surprise that the mortality rate was extremely high and reached 66.6% in our patients; that was comparable to overall mortality of other reported cases ([Table 4](#T4){ref-type="table"}). In this way, blood culture positivity seems to represent not only diagnostic but also a poor prognostic factor.

Apart from blood culture, antigen detection can be useful in diagnosis of arthroconidial fungi because they share a cross-reactivity with cryptococcal glucuronoxylomannan (*T. asahii*, *M. capitatus*), *Aspergillus* galactomannan (*G. candidus*, *M. capitatus*), and β-[D]{.smallcaps}-glucan ([@B57]; [@B6]; [@B48]; [@B56]; [@B73]; [@B16]; [@B21]). In our patients, three out of five (the sixth not tested) had galactomannan index values from 0.5 to 0.7 (the other two ≤ 0.3) at the time of diagnosis of *S. clavata* fungemia ([Table 4](#T4){ref-type="table"}). Available data from other studies showed a lower sensitivity of the galactomannan test and questioned its practical use ([@B60]; [@B21]). In an Italian study, positive β-[D]{.smallcaps}-glucan test results were documented in two out of three patients ([@B21]). To date, the experience with the methods in *S. clavata* infection is little but promising results support further investigation of their clinical usefulness.

Culture-dependent identification of *Galactomyces, Saprochaete*, and *Trichosporon* is limited to AuxaColor (BioRad), API ID32C (BioMérieux) or VITEK 2 system (ID-YST card; BioMérieux). Unfortunately, none of the systems covers *S. clavata*. In general, the accuracy of identification of arthroconidial yeasts by these methods is not reliable ([@B62]). The use of phenotypic tests may be a source of misidentification, especially when cellobiose assimilation is missing ([@B69]; [@B22]). [@B22] described about 15% of *S. clavata* strains that did not assimilate cellobiose. Hence, such "cellobiose-negative *M. capitatus*" strains may have escaped our attention in the past. Recently, the MALDI-TOF mass spectrometry (Biotyper 3.0) has displayed the most promising laboratory tool for determination of and discrimination between arthroconidial fungi, including *S. clavata*, even though reliability varies ([@B68]; [@B44]). ITS, 18S rRNA or protein-coding loci (e.g., *Rbp2*) sequencing may be a reasonable approach to confirm results of other methods (this study, [@B22]; [@B24]; [@B42]).

The role of antifungal susceptibility testing in the management of infections caused by arthroconidial fungi is controversial because of lack of standardized methods. Our MICs were influenced by changing methodologies during the follow-up period (Etest^®^, YeastOne^TM^), but most of them were in line with the results of other studies ([Tables 2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}). The inhibition zones corresponded well with the MICs in case of fluconazole, voriconazole, posaconazole, flucytosine, and echinocandins and disk test may serve as a tentative method for surveillance of *S. clavata* isolates. As no breakpoints and epidemiological cut-off are defined for *S. clavata* yet, interpretation of the susceptibility test results should be done with caution. One has to take into account the clinical form and course of the infection, the pharmacological profile of a given drug or drug formulation, and the presence of risk and predisposing factors in a patient ([@B1]).

Invasive infections caused by arthroconidial fungi typically manifest as fungemia with a tendency to disseminate in immunocompromised patients. They are characterized by a relatively high blood recovery rate and the involvement of different visceral organs such as the lungs, spleen and liver ([@B31]; [@B77]; [@B14]; [@B24]). Our *S. clavata* patients displayed no pulmonary symptoms, even when one patient (No. 5) was positive for bioptic sample of lungs ([Table 1](#T1){ref-type="table"}). This is in contrast to frequently reported findings in more than half of the French outbreak patients ([@B77]). On the other hand, two thirds of our patients have experienced cholelithiasis or cholecystitis, which has been mentioned previously in only one female patient with *S. clavata* infection ([@B21]). That could be due to a relative lack of primary bile salts as a result of gallstone formation and their lower availability for the intestinal microbiota, which converts them to secondary salts with antimicrobial effect on some bacteria and also on *C. albicans* ([@B35]; [@B43]). Alternatively, it may be the result of antibiotic therapy or cholecystectomy that can alter composition of transformation microbiota and indirectly interfere with the production of secondary salt ([@B72]; [@B79]). Microbiota connection is supported with the digestive tract decontamination (gentamicin and/or colistin) to which more than half of French patients have been exposed and suffered from diarrhea ([@B77]). Another risk factor in *S. clavata* infection is anticancer drug cytosine arabinoside (cytarabine) ([@B70]; [@B10]; [@B60]; [@B77]; [@B21]) with specific effect on the neutrophil count and mucosal integrity. Preferential use of more aggressive regimens of cytarabine (≥2000 mg/m^2^ twice daily) in recent years could contribute to *S. clavata* infection, like in case of five of our patients ([@B80]).

A relatively high MIC of fluconazole (≥4 mg/l) in strains isolated from our patients suggested that the prophylactic treatment with the triazole drug could represent a selective pressure for *S. clavata* overgrowth. That is supported with the reports on development of breakthrough infections caused by arthroconidial yeasts in immunocompromised patients on fluconazole or echinocandin prophylaxis or empirical regimen ([@B6]; [@B66]; [@B49]; [@B24]).

Voriconazole remains the drug of choice for *S. clavata* infections despite not all strains display optimal *in vitro* susceptibility results (see Patient No. 2, [Table 1](#T1){ref-type="table"}). This is in line with the recommendation from a panel of experts ([@B1]). On the other hand, liposomal amphotericin B may be an effective alternative; all three Italian patients responded to liposomal amphotericin B and two of them survived (the third died of another cause) ([@B21]). The use of combination therapy remains controversial. Voriconazole and liposomal amphotericin B have provided mixed successes. Adding flucytosine to those drugs as suggested by Lacroix's report and supported *in vitro* data could represent a potentially useful therapeutic modality for both ([Tables 2--4](#T2){ref-type="table"}) ([@B45]; [@B60]; [@B26]; [@B46]; [@B50]). There are limited data about the therapeutic usefulness of posaconazole and isavuconazole ([@B54]; [@B9]). Although the spectrum of activity of these antifungal drugs includes arthroconidial fungi, their MICs suggest that both drugs could be slightly less active on *S. clavata* than voriconazole, maybe, due to a lack of *in vivo* fungicidal activity and/or inadequate pharmacokinetics ([@B78]; [@B30]; [@B59]; [@B24]; [@B25]; [@B23]). This may follow from variable host liver metabolizer status like in voriconazole (*CYP2C19* gene polymorphism) or problematic bioavailability of oral suspension of posaconazole even when the latter problem can be overcome by new formulation of delayed release tablets ([@B58]; [@B81]; [@B51]).

The two main pillars in successful management of infections caused by *S. clavata* are the early administration of antifungal drugs and the control of underlying conditions. While antifungal can safe life for a limited period of time, long-term survival is dependent on the recovery of the underlying hematological disease or neutropenia ([@B10]; [@B60]; [@B21]). The only of our six patient who survived achieved a complete hematopoietic regeneration and presented fewer risk factors (shorter period of deep neutropenia, no urinary catheter, no nasogastric tube, and no parenteral nutrition) with less severe symptomatology (lack of septic shock with MODS) ([Table 1](#T1){ref-type="table"}).

Recovery of *S. clavata* from the blood manifests dissemination stage of life-threatening infection and underlines the urgent need to move the timing of the institution of antifungal therapy before positivity of the blood culture. That supports empirical approach to the therapy using stratification of patients and to start initial treatment based on presence or the accumulation of risk factors, urgency of clinical situation, and availability of other laboratory and clinical data (antigen detection, imaging techniques, previous microbiological findings), including response to current therapy. Therefore, management of *S. clavata* infections is complex that requires close cooperation between the clinicians, microbiologists and epidemiologists.

*Saprochaete clavata* represents an emerging opportunistic fungal pathogen closely associated with AML. Most of the clinical and epidemiological characteristics overlap with the infections caused by other arthroconidial fungi, especially *M. capitatus* and *T. asahii.* Primary source of *S. clavata* is unknown but this yeast is able to colonize humans and under favorable conditions, such as deep and long immunosuppression, to overcome debilitated defense mechanisms and cause life-threatening infection. The prognosis of these invasive infections is generally poor due to lack of the specific clinical signs and symptoms, reliable diagnostic methods, and a limited efficacy of available antifungal drugs. The diagnosis of *S. clavata* infections is usually based on positivity of blood culture; detection of beta-[D]{.smallcaps}-glucan or *Aspergillus* galactomannan can be helpful. The optimal treatment has not been established yet; best results are connected with the application of voriconazole or liposomal amphotericin B, but successful outcome is usually critically dependent on the recovery of underlying conditions associated with immune dysfunction or deficiency.
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